公开(公告)号：US20240360222A1

公开(公告)日：2024-10-31

申请号：US18662493

申请日：2024-05-13

申请人： OSAKA UNIVERSITY

发明人： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH ,  Junichi TAKAGI

IPC分类号： C07K16/28 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09

CPC分类号： C07K16/2839 ,  A61K35/17 ,  A61K39/0011 ,  A61P35/00 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K16/30 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/33

摘要： Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US20240358756A1

公开(公告)日：2024-10-31

申请号：US18599924

申请日：2024-03-08

申请人： Immatics Biotechnologies GmbH

发明人： Ricarda HANNEN ,  Jens HUKELMANN ,  Florian KOEHLER ,  Daniel Johannes KOWALEWSKI ,  Heiko SCHUSTER ,  Oliver SCHOOR ,  Michael ROEMER ,  Chih-Chiang TSOU ,  Jens FRITSCHE

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/4748 ,  C12N5/0636

摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240350603A1

公开(公告)日：2024-10-24

申请号：US18761799

申请日：2024-07-02

申请人： NantBio, Inc. ,  Nant Holdings IP, LLC ,  Nantomics LLC

发明人： Kayvan Niazi ,  Nicholas J. Witchey ,  Stephen Charles Benz ,  Shahrooz Rabizadeh

IPC分类号： A61K39/00 ,  G01N33/50 ,  G01N33/569

CPC分类号： A61K39/0011 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/56977 ,  A61K2039/5158 ,  A61K2039/605 ,  A61K2039/6081

摘要： The invention provides a method of validating the therapeutic composition that is prepared for immunotherapy of a tumor or cancer. The method includes, triggering of an immune response to a neoepitope of a subject's tumor by:



a) obtaining neoepitope sequence data from the tumor of a subject;
b) obtaining immune competent cells;
c) using the neoepitope sequence data to generate a neoepitope presentation system;
d) triggering an immune response by contacting the immune competent cells with the neoepitope presentation system; and
e) quantifying the triggering of the immune response from the contacted immune competent cells.

公开(公告)号：US20240350484A1

公开(公告)日：2024-10-24

申请号：US18645759

申请日：2024-04-25

申请人： EISAI R&D MANAGEMENT CO., LTD.

发明人： Ermira PAZOLLI ,  Silvia BUONAMICI ,  James PALACINO ,  Michael SEILER ,  Ping ZHU ,  Evan BARRY ,  Lihua YU

IPC分类号： A61K31/496 ,  A61K35/17 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K39/00 ,  A61K39/39 ,  A61K39/395

CPC分类号： A61K31/496 ,  A61K35/17 ,  A61K38/191 ,  A61K38/2013 ,  A61K38/2066 ,  A61K38/208 ,  A61K38/2086 ,  A61K38/217 ,  A61K39/0011 ,  A61K39/39 ,  A61K39/3955 ,  A61K2039/6031 ,  A61K2039/6037 ,  A61K2039/6056 ,  A61K2039/6081

摘要： This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.

公开(公告)号：US12121541B2

公开(公告)日：2024-10-22

申请号：US17041305

申请日：2018-06-29

申请人： Iovance Biotherapeutics, Inc.

发明人： Seth Wardell ,  James Bender

IPC分类号： A61K35/17 ,  A01N1/02 ,  A61K9/00 ,  A61K31/675 ,  A61K31/7076 ,  A61K38/20 ,  A61P35/00 ,  C12N5/078 ,  C12N5/0783 ,  A61K38/21 ,  A61K39/00

CPC分类号： A61K35/17 ,  A01N1/0284 ,  A61K9/0019 ,  A61K31/675 ,  A61K31/7076 ,  A61K38/2013 ,  A61P35/00 ,  C12N5/0634 ,  C12N5/0636 ,  C12N5/0638 ,  A61K38/217 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/55533 ,  C12N2501/04 ,  C12N2501/2302 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/24 ,  C12N2501/603 ,  C12N2502/11 ,  C12N2506/30

摘要： The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

公开(公告)号：US20240342305A1

公开(公告)日：2024-10-17

申请号：US18666163

申请日：2024-05-16

申请人： CRAGE MEDICAL CO., LIMITED

发明人： Huamao WANG ,  Bo SONG

IPC分类号： A61K47/68 ,  A61K35/17 ,  A61K39/00 ,  A61K39/395 ,  A61K48/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C07K16/46 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/63 ,  G01N33/574

CPC分类号： A61K47/6879 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/395 ,  A61K48/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/7151 ,  C07K16/2809 ,  C07K16/303 ,  C07K16/46 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/63 ,  A61K2039/5156 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/33 ,  G01N33/57438

摘要： The present invention provides an antibody against glypican-3 (GPC3) and application thereof, and the antibody comprises a single chain antibody and humanized antibody.

公开(公告)号：US20240342261A1

公开(公告)日：2024-10-17

申请号：US18751502

申请日：2024-06-24

申请人： ENTEROME S.A.

发明人： Laurent CHENE ,  Alban MATHIEU ,  Matthieu PICHAUD

IPC分类号： A61K39/00 ,  A61K39/39 ,  A61P35/00

CPC分类号： A61K39/0011 ,  A61K39/00114 ,  A61K39/39 ,  A61P35/00 ,  A61K2039/5158 ,  A61K2039/53 ,  A61K2039/55555 ,  A61K2039/572 ,  A61K2039/6031

摘要： The invention relates to an immunogenic compound comprising an antigenic peptide having amino acid similarity with a tumor antigen, which antigenic peptide is selected in the group consisting of peptides having amino acid similarity with IL13RA2, the said antigenic peptide being selected in the group consisting of sequences described in the specification.

公开(公告)号：US20240342213A1

公开(公告)日：2024-10-17

申请号：US18416459

申请日：2024-01-18

申请人： The Trustees of the University of Pennsylvania ,  Wayne State University

发明人： Carl H. June ,  Michael Milone ,  Yangbing Zhao ,  Lawrence G. Lum ,  Archana Thakur

IPC分类号： A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C07K16/32 ,  C12N5/0783 ,  A61K35/00 ,  A61K39/00

CPC分类号： A61K35/17 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/32 ,  C12N5/0636 ,  A61K35/00 ,  A61K39/0011 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/43 ,  C07K2319/50

摘要： The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an chimeric antigen receptor and bispecific antibodies in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. Certain aspects include modified T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.

公开(公告)号：US12109256B2

公开(公告)日：2024-10-08

申请号：US16919191

申请日：2020-07-02

申请人： Wisconsin Alumni Research Foundation

发明人： Jamey Weichert ,  Paul M. Sondel ,  Anatoly Pinchuk ,  Zachary Morris ,  Mario Otto ,  Bryan Bednarz

IPC分类号： A61K39/00 ,  A61K39/39 ,  A61K39/395 ,  A61K51/04

CPC分类号： A61K39/001 ,  A61K39/0011 ,  A61K39/39 ,  A61K39/39558 ,  A61K51/0408 ,  A61K51/041 ,  A61K51/0489 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55511 ,  A61K2039/55533 ,  A61K2039/572 ,  A61K2039/58 ,  A61K2039/585

摘要： A method of treating a malignant solid tumor in a subject is disclosed herein. The method includes the steps of administering to the subject an immunomodulatory dose of a radiohalogenated compound that is differentially taken up by and retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by intratumorally injecting into (or treating via a separate method) at least one of the malignant solid tumors a composition that includes one or more agents capable of stimulating specific immune cells within the tumor microenvironment. In certain exemplary embodiments, the radiohalogenated compound has the formula:




wherein R1 is a radioactive halogen isotope, n is 18 and R2 is —N+(CH3)3.

公开(公告)号：US20240327832A1

公开(公告)日：2024-10-03

申请号：US18268179

申请日：2020-12-16

申请人： INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY ,  EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION

发明人： Kyuri LEE ,  Hyuk Jin LEE

IPC分类号： C12N15/113 ,  A61K39/00 ,  A61P35/00

CPC分类号： C12N15/113 ,  A61K39/0011 ,  A61P35/00 ,  A61K2039/53 ,  C12N2310/14 ,  C12N2830/50

摘要： The present invention relates to a nucleic acid construct that can express and inhibit a gene simultaneously. The nucleic acid construct that can express and inhibit a gene simultaneously, according to the present invention, comprises both mRNA and siRNA in a single construct, and thus, mRNA and siRNA are introduced simultaneously into the same cell. Accordingly, a protein to be expressed may be expressed normally while expression of a particular gene may be specifically inhibited. The mRNA-siRNA nucleic acid construct activates an immune system by expressing a target protein in an antigen-presenting cell, and at the same time, overcomes interference of immune escape by blocking the activity of an immune checkpoint protein, and thus is expected to be remarkably useful in the fields of immunotherapy, especially in the field of cancer immunotherapy.